Drug intelligence / Profile preview

efavirenz + 2 nrtis

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Oral

Overview

Efavirenz + 2 NRTIs refers to a combination antiretroviral therapy regimen for HIV infection that includes the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz and two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). The most common fixed-dose combinations are: - Efavirenz/emtricitabine/tenofovir disoproxil fumarate (marketed as Atripla) - Efavirenz/lamivudine/tenofovir disoproxil fumarate (marketed as Symfi and Symfi Lo) These regimens are used as first-line therapy for HIV-1 infection in adults and children. Efavirenz acts by noncompetitively inhibiting HIV-1 reverse transcriptase, while the NRTIs act as chain terminators during viral DNA synthesis. This triple-drug combination suppresses viral replication, improves immune function, reduces morbidity/mortality from HIV/AIDS, and lowers transmission risk[4][5][6][8].

Brand names: AtriplaSymfiSymfi Lo
Other names: efavirenz/emtricitabine/tenofovirefavirenz/lamivudine/tenofovir

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on efavirenz + 2 nrtis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on efavirenz + 2 nrtis.

Explore the full profile